|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acute insulin response to glucagon, tolbutamide, and glucose in non-insulin-dependent diabetes of the young.
|
3512209 |
1986 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Islet cell antibodies (ICAs), thyrogastric antibodies, and HLA-DR antigens were determined in 204 patients with type II (non-insulin-dependent) diabetes controlled with diet and/or oral hypoglycemic agents (NIR) and in 108 age-matched patients who required insulin to control their hyperglycemia (IR). beta-Cell function measured as C-peptide response to glucagon was evaluated in relation to the presence of ICAs and HLA-DR antigens.
|
3275559 |
1988 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because GLP-1 has been proposed as a potential agent for treatment of NIDDM, our present data will contribute to the characterization of the receptor binding site and the development of new agonists of this receptor.
|
8405712 |
1993 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
12 identical twin pairs discordant for non-insulin-dependent diabetes mellitus (NIDDM) were studied for insulin sensitivity (euglycemic insulin clamp, 40 mU/m2 per min), hepatic glucose production (HGP, [3-3H]glucose infusion), and insulin secretion (oral glucose tolerance test and hyperglycemic [12 mM] clamp, including glucagon administration).
|
7860750 |
1995 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because glucagon is a key regulator of glucose homeostasis, its receptor, which mediates the actions of glucagon, was considered a candidate gene involved in the pathogenesis of NIDDM.
|
8635644 |
1996 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover in vivo Gly40Ser plays a physiological role in the glucose homeostasis under glucagon control both in NIDDM and non-diabetic subjects.
|
9028723 |
1997 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
The insulinotropic effect of GLP-1 is maintained in patients with Type II (non-insulin-dependent) diabetes mellitus, whereas, for unknown reasons, the effect of GIP is diminished or lacking.
|
9794107 |
1998 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.
|
10415574 |
1999 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients.
|
10826511 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
With the aim of investigating glucose-mediated glucose disposal (glucose effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 diabetes (DM2), and 15 age-, sex-, and BMI-matched control subjects without a family history of DM2, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with somatostatin (360 microg/h), insulin (0.25 mU x kg(-1) x min(-1)), glucagon (0.5 ng x kg(-1) x min(-1)), growth hormone (6 ng x kg(-1) x min(-1)), and tritiated glucose infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at hyperglycemia (approximately 12 mmol/l) over the last 2 h. Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P < 0.04), whereas plasma glucose (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l).
|
10909980 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common polymorphism in the Chinese population was GCA-->GCG (A804A), and its frequency was significantly higher in Chinese patients with NIDDM than in controls (26.5% vs 7.4%, chi 2 = 8.84, P < 0.01).
|
11775217 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.
|
11124853 |
2000 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma glucagon concentrations were similar at basal glycemia (73+/-6, 69+/-5 and 69+/-7 ng/l) and reached peak values of 88+/-9, 88+/-11 and 89+/-7 ng/l at a glycemia of 3.6 mmol/l in MODY3 patients, patients with NIDDM and controls respectively (NS).
|
11174836 |
2001 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results show that insertion of Aha after the 7 position in GLP-1 produces an effective, long-acting GLP-1 analog, which may be useful in the treatment of type 2 diabetes mellitus.
|
11564711 |
2001 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the incretins, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), as well as glucagon and cortisol, are known to influence islet function, the role of these hormones in conditions of insulin resistance and development of type 2 diabetes is unknown.
|
11888847 |
2002 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
The usefulness of synthetic GLP-1 analogs as blood glucose-lowering agents is discussed, and the applicability of GLP-1 as a therapeutic agent for treatment of type 2 diabetes is highlighted.
|
14529486 |
2003 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1(7-36)amide (GLP-1) is an incretin hormone with therapeutic potential for type 2 diabetes.
|
14719796 |
2003 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
We speculated whether GLP-1-based gene therapy could be an approach for treatment of type 2 diabetes.
|
15642594 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied G6PD erythrocyte enzyme activity and the insulin secretory reserve (glucagon-stimulated C peptide) in a cohort of hospitalized West Africans with KPD (n = 59) or type 2 diabetes (T2DM; n = 59) and in normoglycemic controls (n = 55).
|
15914531 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 itself, however, is inactivated rapidly in vivo and thus does not appear to be useful as a therapeutic agent in the long-term treatment of Type 2 diabetes.
|
15780433 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
In recent years, the development of GCGR antisense oligonucleotides and small molecular weight GCGR antagonists have been pursued as possible therapeutic agents to target glucagon action as a treatment for Type 2 diabetes.
|
15948676 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
It was reported that the continuous infusion of GLP-1 normalized the blood glucose level in type 2 diabetes animal model.
|
17045357 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review article summarizes clinical studies on abnormalities in the secretion and insulinotropic effects of GIP and GLP-1 in patients with type 2 diabetes as well as in individuals at high risk.
|
16898571 |
2006 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because of these actions, GLP-1 or GLP-1 receptor agonists are currently being evaluated for the therapy of type 2 diabetes.
|
17928588 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although we still do not know mechanistically how the polymorphisms within the intron regions of TCF7L2 affect the risk of type 2 diabetes, this transcriptional regulator was shown to be involved in stimulating the proliferation of pancreatic beta-cells and the production of the incretin hormone glucagon-like peptide-1 in intestinal endocrine L cells.
|
18599616 |
2008 |